PELTHOS THERAPEUTICS INC

PELTHOS THERAPEUTICS insider sale: a tax‑planning move amid rising share price, executive confidence, and key pipeline milestones shaping its biopharma future.

Pelthos insider RSU grant shows board confidence amid volatile biotech stock—key for investors watching CT2000 trial and regulatory milestones.

Insider buying at Pelthos shows confidence in its early‑stage ocular pain therapy; see how incremental purchases and trial milestones could drive future value.